FDA approves first MS drug
FDA officials have approved the first drug designed to improve the ability to walk in patients suffering from multiple sclerosis (MS).
Multiple sclerosis (MS) is a potentially debilitating disease in which the body's immune system attacks the protective sheath that covers the central nervous system, causing numbness or paralysis of arms and legs.
The ability to walk tends to worsen over time in MS patients and in some cases they might need to use wheelchairs. There is no cure for the disease affecting about 2.5 million individuals worldwide.
According to the FDA statement released on Friday, MS patients on Ampyra (dalfampridine) have faster walking speeds. These patients were able to walk longer distances, be on their feet longer, climb stairs easier, and perform other walking functions better.
The drug was reported to enhance nerve function in MS sufferers. It, however, did not influence the course of the disease.
‘There is no indication this type of treatment slows the progressive nature of the disease process,’ said Andrew D. Goodman, MD, director of the MS center at the University of Rochester.
‘But there is every indication that at whatever level of function an MS patient may have, there may still be room for improvement with this type of treatment,’ he added.
While the oral drug is reported to be safe and effective, it may cause seizure in patients taking higher-than-recommended doses. The drug is not recommended in patients already suffering from moderate to severe kidney disease.
The manufacturers hope the drug will enter the market soon.
Source: presstv.ir
Other links:
Mediterranean diet reduces risk of depression
Menopause increases bad cholesterol levels
Coffee cuts exercise-induced asthma
Vegetarian diet cuts blood cancer risk
Promising results for trial HIV vaccine
High-fructose diets impair memory
Secret behind gray hairs found
Low-fat diet can improve mood
